FDA approves higher-dose Wegovy for obesity treatment
The Facts
- The U.S. Food and Drug Administration approved a higher-dose 7.2-milligram version of Wegovy, called Wegovy HD, for obesity treatment and weight-loss maintenance.
- Novo Nordisk said Wegovy HD will be launched in the United States in April 2026.
- Clinical trial data cited by Novo Nordisk showed Wegovy HD led to average weight loss of about 20.7% at 72 weeks.
- The new 7.2-milligram dose is higher than Wegovy’s previously approved maximum dose of 2.4 milligrams.
- The FDA said the approval was granted through its Commissioner's National Priority Voucher program and came 54 days after the review request was approved.
- Novo Nordisk is positioning the higher-dose Wegovy to compete more directly with Eli Lilly’s obesity drug Zepbound.
Context
How much more weight did patients lose on the higher-dose version?
Novo Nordisk said the STEP UP trial showed an average weight loss of 20.7% at 72 weeks with the 7.2-milligram dose NDTV Sherwood News. Some reports also said about one-third of participants lost at least 25% of their body weight Investing.com India Healio.
When will Wegovy HD be available in the U.S.?
Novo Nordisk said it expects to launch Wegovy HD in the United States in April 2026, with reports saying it will be sold through pharmacies and, in some cases, cash-pay and pharmacy channels NDTV Bloomberg Business U.S. News & World R….
Why was the approval notable for the FDA?
The FDA said the decision was made under its Commissioner's National Priority Voucher program, which is intended to speed review of selected drugs; the agency said the approval came 54 days after the review request was approved Reuters U.S. Food and Drug ….
The receipts — 34 sources
Wire services (3)
Independent coverage (31)
The news, read by both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.